Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Genentech executes another round of layoffs, with 3 VPs axed
(1h)
AI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data finds
(2h)
Novo reports data breach, tells clinical trial patients to 'remain vigilant'
(2h)
Beyond Rigid Platforms: Adaptive Adenoviral Platform De-Risks Development to GMP
(4h)
Roche nabs EU approval on label expansions for companion dx platform
(6h)
Predicta links with Spanish university to offer diagnostic for blood cancers
(7h)
Cardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPO
(7h)
Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3
(10h)
Fierce Biotech heading to UK to host event amid London Life Sciences Week
(10h)
Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown
(12h)
BioPharma Dive
Summit pulls $500M share sale a day after announcing it
(3h)
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
(3h)
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
(5h)
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
(8h)
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
(1d)
Sanofi stops immune drug trial in latest research setback
(1d)
Parabilis sets a record with a $670M biotech IPO
(1d)
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
(1d)
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
(2d)
Stealthy startup Treeline plans a reverse merger
(2d)
Endpoints News
Inside Makary’s ouster; Another win for Lilly’s triple-G; and more
(3w)
FDA clears Gilead's hepatitis D drug, four years after prior rejection
(3w)
GOP lawmaker asks Trump administration to curb China biotech deals
(3w)
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
(3w)
How Utah’s AI prescribing experiment is going so far
(3w)
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
(3w)
Tender offer for Recordati; Sobi's gout drug passes Phase 3 test
(3w)
Why one health AI unicorn is giving away its service for free
(3w)
Novartis says Avidity's science could apply beyond muscular dystrophies
(3w)
Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
(3w)
BioSpace
Genentech R&D layoffs hit top exec who’s been with the biotech nearly 30 years
(4h)
Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs
(5h)
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial
(6h)
SonoThera bags $125M series B to advance safer gene therapies
(7h)
Novartis tightens bond with Orionis in up to $1.4B molecular glue deal
(8h)
Portugal, Spain and the new biotech frontier
(11h)
The wait continues: pressure to operate lean among factors behind slow job market
(12h)
May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech
(12h)
Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy
(1d)
Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug
(1d)
STAT News
Nonprofit buys experimental cancer drug to maintain patient access
(52m)
Study highlights influence of socioeconomic status on children’s brain development
(1h)
Abridge inks deals with Nvidia and Lilly
(2h)
A suspicious denial pattern in Medicare Advantage
(4h)
Novartis doubles down on molecular glue strategy
(5h)
We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
(6h)
‘Synthetic lethality’ could trigger another round of biotech MA
(7h)
Enliven Therapeutics’ leukemia drug shows promise in new study
(7h)
HHS responds coolly to paper on alcohol risk
(7h)
Scientists see promise in NIH proposal to cap number of grants they receive
(10h)
BioPharma Trend
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2w)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(1mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(2mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(2mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(2mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(2mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(2mo)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(2mo)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(2mo)
Drug Channels
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)
(8h)
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update (rerun)
(1d)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments (rerun)
(2d)
The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies (rerun)
(3d)
Pharmacy Copay Misuse: The Multi-Billion Dollar Issue Hiding In Plain Sight
(6d)
The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs
(1w)
Drugs, Discounts and Data: Crafting Sustainability in an Imperfect System
(2w)
Drug Channels News Roundup, May 2026: My $0.02 on Optum Rx’s Transparency, Must-Read 340B History, PBM Unbundling Update, PA Delays, and Vegas Fun
(2w)
PBM Shakeout: How Vertical Integration Is Reshaping What’s Next (VIDEO)
(3w)
Protecting Gross-to-Net Performance Through Single-Channel Ecosystems
(4w)
European Biotechnology Magazine
Novartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bn
(7h)
Heidelberg-based Veraxa ventures onto Nasdaq in turbulent market environment
(11h)
Scenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’s
(11h)
Sanofi’s $11.6bn Bioverativ purchase looks hit-and miss after phase 3 rare diseases drug runs into trouble
(1d)
Circio completes NOK300m financing to fund circular RNA platform development
(1d)
AlzeCure shares soar over 300% after Eli Lilly strikes Alzheimer’s deal worth over $1bn
(1d)
Boehringer/Zealand obesity drug delivers Phase III weight loss, but side effects raise questions
(2d)
Bial drops pariceract after Phase IIb failure in GBA-associated Parkinson’s
(2d)
GSK taps Engitix’s platform in liver fibrosis deal worth up to £44.5m upfront
(3d)
Next-gen oligonucleotides to transform patient care
(3d)
Drug Hunter
Locking the Sec61 Gate to Corral Disease
(4h)
linerixibat
(1d)
NVP-INE963
(2d)
sonrotoclax (BGB-11417)
(3d)
Module 4 Quiz
(3d)
Brushstrokes of Biology: Cell Painting for Mechanism of Action
(6d)
tazemetostat
(1w)
acoziborole
(1w)
milsaperidone
(1w)
PF-06826647
(1w)
Labiotech.EU
How Daiichi Sankyo aims to become a top five oncology player by 2035
(1d)
Beyond amyloid and dopamine: emerging technologies reshaping neurology
(1d)
Pharma in Spain: why global investors and innovators are moving in
(2d)
Top biotech deals in May 2026
(3d)
Eight oncology deals in 2026 spotlight where industry leaders are betting big
(6d)
Eight oncology deals in 2026 spotlight where industry leaders are betting big
(6d)
Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media
(6d)
Highlights of ASCO 2026: how is cancer care evolving?
(1w)
Surge in M&As driven by patent expirations
(1w)
The biggest biotech funding rounds in May 2026
(1w)
Bio IT World
Navigating the Perilous Journey from Lab to Market
(1d)
As AI Reshapes Drug Discovery the Lab Remains the Bottleneck
(2d)
Federation Plus Fine Tuning: The Push for Federated Learning Models Continues
(1w)
Trends from the Trenches: AI-Ready Life Sciences Data
(1w)
A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs
(1w)
Immunai, AstraZeneca Expand Partnership, Rancho Biosciences Releases Multi-omics Datasets, Dotmatics AI Co-Scientist
(2w)
Insilico Medicine, Human Longevity Partner for Longevity Foundation Model
(2w)
Bio-IT World VIP Conference: Exploring Breadth vs. Depth
(2w)
Follow the Money: AI Drug Design Engine, Treating Multiple Myeloma, Quantum Healthcare Platform
(2w)
At Bio-IT World's 25th Anniversary, Rare Disease Takes Center Stage
(3w)
GEN News
Potential Cocaine Addiction Targets Identified Through Genetic Mapping in Rats
(1h)
New mRNA Delivery Platform Restores Muscle Function in DMD Models
(2h)
Fighting Antimicrobial Resistance with Biomaterials and Phages
(3h)
GSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC Treatments
(22h)
Origins of First Eukaryotes Linked to Contributions from Multiple Bacteria and Giant Viruses
(23h)
Brain Aneurysm Study Identifies Structural, Immune Markers of Rupture Risk
(23h)
Symeres Expands Spray Drying Capabilities at Its U.S. New Jersey Site
(1d)
In Silico Devices May Improve Drug Manufacturability
(1d)
Gorilla Adenovirus Brings Natural Edge to Cancer Therapy
(1d)
Updated Amplification Tool Rapidly Detects Mycoplasma
(1d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(2mo)
Understanding High-Risk Essential Thrombocythemia
(2mo)
Son’s Decision to Donate Gave His Father a Second Chance
(2mo)
Functional Precision Medicine Advances Brain Tumor Care
(2mo)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(2mo)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(2mo)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(2mo)
How Honest Conversations Strengthened a Couple After Cancer
(2mo)
Cardiac Health in Cancer Survivors: A Growing Need
(2mo)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(2mo)
Contract Pharma
Harbour BioMed Adds Luisa Salter-Cid as Scientific Advisor
(25m)
PharmaEssentia Acquires Forus Therapeutics, Expanding Footprint in Canada
(1h)
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B
(4h)
ACG Packaging Materials Achieves ISO Certification for Croatia Facility
(5h)
Cytovance Biologics Adds Cell Line Development Services
(5h)
Verge Labs, Tenacia Biotech Unite to Advance CNS Pipeline
(1d)
Axplora to Consolidate UDCA Manufacturing at Vizag, India Site by End of 2026
(1d)
Genesis and Alnylam Expand Partnership to Commercialize RNAi Therapeutics for Nordic Region
(1d)
Symeres Expands Spray Drying Capabilities in Cranbury, NJ
(1d)
FibroFind Names New CEO, Adds Three Senior Hires
(1d)
Pharma Times
NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
(9h)
Anocca doses first patients with precision TCR‑T therapy
(10h)
Connecta launches phase 2a trial of neuroplasticity modulator
(1d)
Aquipta recommended by NICE for acute migraine treatment
(1d)
Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
(2d)
Alzecure enters collaboration and with Lilly for Alzheimer’s project
(2d)
Survodutide trial data show targeted visceral and liver fat reductions
(3d)
Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
(1w)
European approval enables measles protection with CSL’s immunoglobulin Privigen
(1w)
JJP Biologics reports positive interim phase 1b data for nebaprubart
(1w)
Medcity News
Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease
(1h)
From Copilots to Clinical Judgment: The Next Phase of AI in Digital Behavioral Health
(5h)
AI Is Scaling Healthcare Costs Because the System Was Built That Way
(5h)
What Healthcare Leaders Get Wrong About EHR Switching
(5h)
The Identity Gap Undermining Value-Based Care
(7h)
DiMe Launches New Initiative for Virtual-First Care
(19h)
‘2030 Scares Me to Death’: Credit Analysts’ Urgent Warning for Healthcare CFOs
(23h)
Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO
(1d)
Restoring the Patient-Clinician Relationship to the Center of Care
(1d)
From Detection to Defense: Building Fraud-Resilient Healthcare Payment Systems
(1d)
Chemical & Engineering News
Toxic chemicals accumulate in vapes as their juice runs low
(58m)
A new, ultrabright laser powers a cryo-EM advance 15 years in the making
(1h)
Coenzyme works as a molecular brake for labor
(1h)
Freepoint Eco-Systems shuts down controversial plastics pyrolysis plant
(2h)
Evonik plans revamp to make R&D go faster
(3h)
Meet Jasmine Clark, the self-described ‘mad scientist’ running for the US House
(3h)
Consortium takes on challenges of advancing sustainable materials use commercially
(7h)
Barry Snider receives 2026 Paul G. Gassman Distinguished Service Award
(23h)
Google DeepMind and Sanger Institute form AI genomics consortium
(1d)
Twistronics founders win 2026 Kavli Prize in Nanoscience
(1d)
The Pharma Letter
City Therapeutics
(1h)
Wegovy pill becomes first and only daily GLP-1 weight loss tablet approved in UK
(4h)
Takeda’s zasocitinib outperforms deucravacitinib in PsO
(4h)
From raising awareness to developing treatments, Alexion is fighting HPP battle on many fronts
(4h)
Richter and Hetero collaborate on Ozempic generic
(5h)
Oriva appoints Agnès Arbat as CEO as endometriosis drug enters clinic
(7h)
Grifols breaks ground on new manufacturing site in Spain
(7h)
FDA accepts Roche’s Tecentriq sBLA for priority review
(8h)
Beren lines up $300 million ahead of potential adrabetadex launch
(8h)
Glenmark launches Winlevi in Europe
(8h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(2mo)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(2mo)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(2mo)
Treating Triple Negative Breast Cancer in the Frontline Setting
(2mo)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(2mo)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(2mo)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(2mo)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(2mo)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(2mo)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(2mo)
MedWatch
US employers are considering dropping coverage for GLP-1 medications in 2027
(7h)
EU court urged to prioritize vaccine contract transparency over corporate interests
(7h)
EU’s new medicines act strikes a difficult balance
(8h)
Pfizer to adjust planned investments in Germany after new pricing policy
(8h)
Johnson & Johnson acquires Firefly Bio for USD 1 billion
(10h)
Teva buys Emalex Biosciences, gains late-stage drug access
(11h)
Amgen secures extension of Norwegian agreement after withdrawal from Danish market
(12h)
Eli Lilly takes weight-loss pill ad to the NBA Finals
(12h)
Analysts see prospects for upward revision at Demant after strong 2026 start
(1d)
Novo-owned weight-loss company appoints biotech executive as chairman following management shake-up
(1d)
In The Pipeline
Hydroxyl Radicals In Water Droplets? Doesn't Look Like It.
(2h)
A New Antibiotic Idea From An Old Source
(1d)
Insights Into Idiopathic Pulmonary Fibrosis
(2d)
Unusual Toxicity With a Protein Degrader Molecule
(3d)
The Causes of Long Covid
(7d)
Action! Action Now.
(1w)
The Current Crisis: What's Happening to Science in America
(2w)
Evaluating "Co-Scientist", a New AI Science System
(2w)
That Methyl Methacrylate Tank
(2w)
Reading the Labels on Mutant Mice
(3w)
Pharmaphorum
UK approves Novo Nordisk's Wegovy pill
(2h)
Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest
(3h)
J&J adds rare disease wAIHA to Imaavy's potential uses
(6h)
Novartis gets win for another Avidity muscular dystrophy AOC
(7h)
Basketball great Shaq fronts Lilly sleep apnoea campaign
(8h)
Anthropic puts life sciences at heart of new AI model
(9h)
SonoThera's $125m Series B heads recent biofinancings
(11h)
Lilly wins new FDA approval for eczema drug Ebglyss
(1d)
Bayer's asundexian starts EU review for ischaemic stroke
(1d)
AbbVie's migraine drug cleared for migraine attacks on NHS
(1d)
Drug Discovery Weekly
DaltonTx launches AI drug discovery platform
(5h)
Webinar – The orchestrated lab: Moving beyond siloed automation
(8h)
Bead BioPharma emerges from stealth with novel drug platform
(9h)
AMR Bio confirms contribution to US National Action Plan
(10h)
Webinar: Overcome critical bottlenecks in fragment-based drug discovery
(11h)
GLP-1 reduces liver fat by 63%, trial results show
(1d)
From undruggable to inevitable
(1d)
NICE recommends quadruplet regimen for multiple myeloma
(1d)
UK cancer patients to benefit from genetic testing rollout
(1d)
Webinar: Modernise and scale your antibody discovery programmes
(1d)
HIT Consultant
Why Validation is Becoming the Proving Ground for AI in Life Sciences
(4h)
Med-Metrix Acquires CanAide to Automate Patient Access
(5h)
Surgical AI Startup Uncovr Emerges from Stealth with $7M Seed Funding
(7h)
Scispot Secures $8M to Expand AI-Native Operating Layer for Modern Labs
(2d)
Hybrid Care 2.0: How AI-Powered Telehealth and Predictive Analytics Are Redefining Medicine
(2d)
Blue Cross MA Inks Its First Oncology Value-Based Deal with Thyme Care
(2d)
Stepful Secures $55M to Expand AI-Powered Healthcare Workforce Training
(2d)
AGS Health Launches InnovationWorks™ Center of Excellence to Scale Revenue Cycle AI
(2d)
Tegria Appoints Former TriZetto CEO Craig Mengert to Succeed Retiring Brian Cahill
(2d)
Klinic Inc. Secures $24M to Scale Specialty Care Enablement Platform
(2d)
Insights: Pink Sheet
UK’s HRA Maps Path To Regulatory Clarity For AI-Enabled Trials
(4h)
US-Approved Drugs Otarmeni, Idvynso And Unloxcyt Filed In EU
(6h)
Asundexian, Venglustat And Japanese Encephalitis Vaccine Among Latest EU Filings
(6h)
Japan Grapples With Off-Label Mounjaro Trade For Weight Loss
(11h)
Policy Priorities For An Innovative Korean Ecosystem
(15h)
BIOSECURE Legal Lifeline Available For Pharma Companies Using WuXi AppTec … For Now
(21h)
BsUFA IV: US FDA Willing To Select Products For Exclusivity Determinations Each Year
(23h)
Riddle Of The Sphinx: Reading Into US FDA’s Striking Silence At NPV Hearing
(1d)
Industry Urges EU To Broaden SPC Scope Under Biotech Act
(1d)
Alexion: EU JCAs Could Be A ‘Drag On Competitiveness’ Without Orphan Drug Flexibility
(1d)
BioXconomy
New study reveals $35 as tipping point for prescription abandonment
(1h)
Japan urged to regulate generative AI in clinical trials
(2h)
Dodging the cytokine storm: Delivering ASOs without adverse effects
(5h)
Lilly adds to neuroscience portfolio with $1bn AlzeCure Alzheimer's pact
(6h)
Sofinnova and AWS deliver AI to portfolio companies’ door
(7h)
African and European regulators prepare trials for Bundibugyo Ebola vaccines, treatments in DRC
(1d)
Legal roundup: DOJ speeds up fraud probes, more
(1d)
Parabilis Medicines sets $20 share price in $670m IPO
(1d)
J&J sets DACs on fire with $1bn acquisition of Firefly Bio
(1d)
From study design to investor confidence: De-risking early-stage biotech
(2d)
BioCentury
Pinnacle: Designing oral peptides to close the gap with injectable biologics
(19h)
Moving faster at the academia-industry interface — a BioCentury podcast
(20h)
LRRK2 inhibitor failure pushes Parkinson’s field toward genetic enrichment
(20h)
Where Parabilis’ massive IPO ranks among biotech debuts on NASDAQ
(21h)
The race for a vaccine against rare Ebola virus
(1d)
MHRA proposes pairing trial authorization with market access for very rare diseases
(1d)
In third deal under Miels, GSK adds targeted cancer therapies via $10.6B Nuvalent buy
(1d)
Impact of Biosecure starting to come into focus
(1d)
Calmer waters for FDA; Servier, Lilly deals — a BioCentury podcast
(2d)
Sizing up Lilly’s dealmaking spree
(2d)
SCRIP
ADA 2026: Roche Still Looking For Ways To Stand Out In Obesity
(3h)
Executives On The Move: Four CEOs And Five CFOs Among This Week’s Changes
(5h)
US Drug Shortages Ease But Discontinuations Surge, Asia Supply Chain Risks Run Deep
(6h)
Positive Del-Brax Biomarker Data Offers Early Support For Novartis’s Avidity Bet
(6h)
Orionis Back In Novartis’s Orbit With New Molecular Glue Deal
(6h)
Ambitious Oriva Wants To Be Key Player In Women’s Health
(10h)
Parabilis Breaks Kailera’s Short-Lived Biopharma IPO Record
(21h)
SonoThera Raises $125m To Advance Next-Gen DMD Gene Therapy
(21h)
J&J Opts Not To Follow The Oncology Crowd
(22h)
ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations
(1d)